0 CHECKOUT

Keratitis - Pipeline Review, H1 2015

  • ID: 3259622
  • April 2015
  • 70 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Dompe Farmaceutici S.p.A.
  • Sirnaomics, Inc.
  • The Medicines Company
  • MORE

Keratitis - Pipeline Review, H1 2015

Summary

This, ‘Keratitis - Pipeline Review, H1 2015’, provides an overview of the Keratitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Dompe Farmaceutici S.p.A.
  • Sirnaomics, Inc.
  • The Medicines Company
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Keratitis Overview
Therapeutics Development
Pipeline Products for Keratitis - Overview
Pipeline Products for Keratitis - Comparative Analysis
Keratitis - Therapeutics under Development by Companies
Keratitis - Therapeutics under Investigation by Universities/Institutes
Keratitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Keratitis - Products under Development by Companies
Keratitis - Products under Investigation by Universities/Institutes
Keratitis - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corporation
Cellceutix Corporation
Dompe Farmaceutici S.p.A.
Lee's Pharmaceutical Holdings Limited
Peregrine Pharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
Sirnaomics, Inc.
The Medicines Company
Keratitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-31G - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LQ-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
moxifloxacin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGN-632 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PIM-45 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Nerve Growth Factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-259 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STP-601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tigecycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Keratitis - Recent Pipeline Updates
Keratitis - Dormant Projects
Keratitis - Product Development Milestones
Featured News & Press Releases
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Keratitis, H1 2015
Number of Products under Development for Keratitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015
Keratitis - Pipeline by Cellceutix Corporation, H1 2015
Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H1 2015
Keratitis - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015
Keratitis - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015
Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015
Keratitis - Pipeline by Sirnaomics, Inc., H1 2015
Keratitis - Pipeline by The Medicines Company, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Keratitis Therapeutics - Recent Pipeline Updates, H1 2015
Keratitis - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Keratitis, H1 2015
Number of Products under Development for Keratitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Adamis Pharmaceuticals Corporation
Cellceutix Corporation
Dompe Farmaceutici S.p.A.
Lee's Pharmaceutical Holdings Limited
Peregrine Pharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
Sirnaomics, Inc.
The Medicines Company

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.